These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30430714)

  • 41. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma.
    van Sandick JW; van Lanschot JJ; Kuiken BW; Tytgat GN; Offerhaus GJ; Obertop H
    Gut; 1998 Aug; 43(2):216-22. PubMed ID: 10189847
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
    Shaheen NJ; Inadomi JM; Overholt BF; Sharma P
    Gut; 2004 Dec; 53(12):1736-44. PubMed ID: 15542506
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off.
    Masclee GM; Coloma PM; de Wilde M; Kuipers EJ; Sturkenboom MC
    Aliment Pharmacol Ther; 2014 Jun; 39(11):1321-30. PubMed ID: 24738722
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preferences for Surveillance of Barrett's Oesophagus: a Discrete Choice Experiment.
    Bulamu NB; Chen G; Bright T; Ratcliffe J; Chung A; Fraser RJL; Törnqvist B; Watson DI
    J Gastrointest Surg; 2019 Jul; 23(7):1309-1317. PubMed ID: 30478530
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Barrett's oesophagus: endoscopic diagnosis and follow-up].
    Ponsot P
    Ann Chir; 2006 Jan; 131(1):3-6. PubMed ID: 16376849
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adenocarcinoma and Barrett's oesophagus. A clinico-pathological study.
    Moghissi K; Sharpe DA; Pender D
    Eur J Cardiothorac Surg; 1993; 7(3):126-31. PubMed ID: 8461144
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Barrett's oesophagus: a review of costs of the illness.
    Arguedas MR; Eloubeidi MA
    Pharmacoeconomics; 2001; 19(10):1003-11. PubMed ID: 11735670
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel.
    Duits LC; Phoa KN; Curvers WL; Ten Kate FJ; Meijer GA; Seldenrijk CA; Offerhaus GJ; Visser M; Meijer SL; Krishnadath KK; Tijssen JG; Mallant-Hent RC; Bergman JJ
    Gut; 2015 May; 64(5):700-6. PubMed ID: 25034523
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results.
    Sharma P; Wani S; Weston AP; Bansal A; Hall M; Mathur S; Prasad A; Sampliner RE
    Gut; 2006 Sep; 55(9):1233-9. PubMed ID: 16905695
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Barrett's oesophagus: Current controversies.
    Amadi C; Gatenby P
    World J Gastroenterol; 2017 Jul; 23(28):5051-5067. PubMed ID: 28811703
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study.
    Ross-Innes CS; Chettouh H; Achilleos A; Galeano-Dalmau N; Debiram-Beecham I; MacRae S; Fessas P; Walker E; Varghese S; Evan T; Lao-Sirieix PS; O'Donovan M; Malhotra S; Novelli M; Disep B; Kaye PV; Lovat LB; Haidry R; Griffin M; Ragunath K; Bhandari P; Haycock A; Morris D; Attwood S; Dhar A; Rees C; Rutter MD; Ostler R; Aigret B; Sasieni PD; Fitzgerald RC;
    Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):23-31. PubMed ID: 28404010
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Impact of endoscopic surveillance of Barrett's esophagus on survival of patients with esophageal adenocarcinoma].
    Incarbone R; Bonavina L; Bassi F; Peracchia A
    Chir Ital; 2002; 54(5):591-6. PubMed ID: 12469454
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota.
    Conio M; Cameron AJ; Romero Y; Branch CD; Schleck CD; Burgart LJ; Zinsmeister AR; Melton LJ; Locke GR
    Gut; 2001 Mar; 48(3):304-9. PubMed ID: 11171817
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stepwise radical endoscopic resection for eradication of Barrett's oesophagus with early neoplasia in a cohort of 169 patients.
    Pouw RE; Seewald S; Gondrie JJ; Deprez PH; Piessevaux H; Pohl H; Rösch T; Soehendra N; Bergman JJ
    Gut; 2010 Sep; 59(9):1169-77. PubMed ID: 20525701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
    Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
    Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neoplastic Barrett's oesophagus and long-term follow-up after endoscopic therapy: complete histological eradication of Barrett associated with high-grade dysplasia significantly decreases neoplasia relapse.
    Caillol F; Godat S; Autret A; Bories E; Pesenti C; Ratone JP; Poizat F; Guiramand J; Delpero JR; Giovannini M
    Surg Endosc; 2016 Dec; 30(12):5410-5418. PubMed ID: 27129553
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk of Barrett's oesophagus, oesophageal adenocarcinoma and reflux oesophagitis and the use of nitrates and asthma medications.
    Ladanchuk TC; Johnston BT; Murray LJ; Anderson LA;
    Scand J Gastroenterol; 2010 Dec; 45(12):1397-403. PubMed ID: 20626305
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma.
    Sonnenberg A; Soni A; Sampliner RE
    Aliment Pharmacol Ther; 2002 Jan; 16(1):41-50. PubMed ID: 11856077
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Med J Aust; 2004 Apr; 180(8):387-91. PubMed ID: 15089728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular evaluation of ablative therapy of Barrett's oesophagus.
    Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
    J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.